FindTrial
Sign In

Effects of brain electrical stimulation combined with speech therapy on the voice and speech of individuals with Parkinson’s disease

Effects of tDCS combined with speech therapy on the voice and speech of individuals with Parkinson’s disease: a randomized clinical trial with follow-up.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8q6kj3n
Enrollment
Unknown
Registered
2025-12-01
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

transcranial direct current stimulation

Interventions

This is a Randomized Clinical Trial with a parallel-group design (2 arms), triple-blind, and longitudinal (follow-up after 3 months) involving individuals with Parkinson&apos
s Disease (PD). Participants will be randomly divided into: experimental group (EG) - receiving the tDCS intervention + conventional speech therapy
and control group (CG) - receiving sham tDCS (electrodes positioned without the application of electrical current) + conventional speech therapy. The EG will consist of 21 participants and the CG will
on&quot
phase of medication, and present some complaint regarding their voice and/or speech.

Sponsors

Departamento de Fonoaudiologia
Lead Sponsor
Departamento de Fonoaudiologia
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Individuals with a medical diagnosis of Parkinson’s disease, at stages I to IV on the Hoehn & Yahr scale, aged over 18 years, of both sexes; being in the “on” medication state during the collection of voice samples; presenting some self-reported or clinically detected communication complaint related to speech and/or voice, as identified by the evaluator during the initial contact

Exclusion criteria

Exclusion criteria: Individuals with severe cognitive or motor impairments that prevent comprehension and/or proper execution of the proposed exercises; pregnant women; individuals reporting other neurological or psychiatric disorders; history of seizures/epileptic crises; previous laryngeal surgery; or history of head and neck surgery (such as deep brain stimulation). Participants who miss more than one session or experience any serious adverse event will be excluded from the study

Design outcomes

Primary

MeasureTime frame
It is expected that participants receiving neuromodulation combined with conventional speech therapy will show better outcomes, with subglottic/glottic-level changes leading to optimized vocal stability, and supraglottic-level improvements reflected in articulation, resonance, and prosody.—

Secondary

MeasureTime frame
No secondary outcomes are expected.—

Countries

Brazil

Contacts

Public ContactJulianne Teixeira

Universidade Federal de Pernambuco

julianne.teixeira@ufpe.br+55(81)2126-7518

Outcome results

None listed

Source: REBEC (via WHO ICTRP)